ICH M4Q(R2): The Evolution of Quality Module Submissions

Comparing M4Q(R1) and M4Q(R2) and Preparing for the Digital Future

Introduction

The ICH M4Q guideline has served as the backbone of quality module submissions since 2002, establishing a globally harmonized framework for organizing Chemistry, Manufacturing, and Controls (CMC) data. Now, with M4Q(R2) currently in Step 2 consultation, we stand at a pivotal moment in regulatory evolution for quality module. This revision represents far more than structural adjustments as it signals a strategic transformation toward digital-first, science-driven regulatory submissions.

For professionals in regulatory affairs, quality assurance, and pharmaceutical development, understanding the transition from M4Q(R1) to M4Q(R2) is essential for preparing organizations for the future of quality module in regulatory submissions.

Why M4Q(R2) Matters

M4Q(R1), implemented in 2002, successfully harmonized quality information formats across regions. However, the pharmaceutical landscape has fundamentally transformed over the past two decades:

• Novel therapeutic modalities including biologics, cell and gene therapies, and advanced therapy medicinal products (ATMPs)

• Advanced manufacturing technologies such as continuous manufacturing and process analytical technology (PAT)

• Quality-by-Design (QbD) principles embedded in ICH Q8-Q14 guidelines

• Digital transformation demands for structured, machine-readable data

• Lifecycle management approaches requiring more efficient post-approval change protocols

M4Q(R2) addresses these modern realities by providing a framework that supports digital submissions, facilitates efficient regulatory review, and accommodates the full spectrum of current and emerging product types.

Key Structural Changes: M4Q(R1) vs. M4Q(R2)

1. Enhanced Module 2.3: The New Strategic Core

M4Q(R1): Module 2.3 served as a Quality Overall Summary (QOS), providing a general overview of Module 3 content.

M4Q(R2): Module 2.3 is restructured into six distinct subsections (2.3.1 through 2.3.6), transforming it into the

The three most critical subsections for regulatory efficiency are:

• 2.3.3 – Core Quality Information (CQI): Critical quality attributes, specifications, and control strategies presented in a clear, granular format for efficient regulatory assessment

• 2.3.4 – Development Summary and Justification (DSJ): Pharmaceutical development rationale linking Quality Target Product Profile (QTPP) to control strategy, with integrated justifications for cross-cutting topics like extractables/leachables and adventitious agents as well as justifications for established conditions (ECs) as per ICH Q12

• Product-Specific and Platform Information sections: Optional sections providing flexibility for novel products and platform technologies

2. Reorganized Module 3: Supporting Data Repository

M4Q(R1): Module 3 contained both summaries and detailed supporting data in a combined format.

M4Q(R2): Module 3 (now designated 3.2) serves exclusively as the repository for supporting data following a standardized Description, Manufacture, Control, and Storage (DMCS) template with explicit cross-references to Module 2.3.

This clear separation between core information (Module 2.3) and supporting data (Module 3.2) reduces duplication and enhances regulatory efficiency.

3. Improved Clarity for Drug Substance and Drug Product

M4Q(R2) provides clearer separation and organization for drug substance and drug product information, including distinct sections for starting materials, intermediates, and excipients. This granularity supports more efficient review and lifecycle management.

M4Q Evolution

Aspect	M4Q(R1) – 2002 Implemented	M4Q(R2) – 2027 Expected
Module 2.3 Structure	General Quality Overall Summary (QOS)	Six structured subsections (2.3.1-2.3.6) including Core Quality Information and Development Summary
Module 3 Focus	Combined summaries and supporting data	Supporting data only (Module 3.2) with standardized DMCS template
QbD Integration	Limited structured integration	Full integration of ICH Q8-Q14 principles with QTPP, control strategy, and lifecycle management
Product Scope	Primarily chemical entities	All pharmaceutical and biological products including biologics, ATMPs, combination products, and platform technologies
Digital Readiness	PDF-based narrative submissions	Structured, granular data designed for digital submissions and eCTD 4.0
Lifecycle Management	Limited structural support for post-approval changes	Enhanced support via ICH Q12 integration with modular, cross-linked structure for efficient updates

Strategic Benefits of M4Q(R2)

1. Regulatory Efficiency

With Module 2.3 as the focal point for regulatory assessment, reviewers can rapidly access critical quality information without navigating extensive supporting documentation. This streamlines initial review timelines and reduces time to approval.

2. Reduced Duplication and Enhanced Consistency

Cross-referencing between Module 2.3 and Module 3.2 eliminates redundant narratives and ensures consistency across the dossier. This reduces document preparation time and minimizes discrepancies that can trigger regulatory questions.

3. Flexibility for Innovation

Optional product-specific (such as Substance Intermediate, SI) and platform information (Product Intermediate, PI) sections provide the flexibility needed for novel therapeutic modalities, platform technologies, and emerging manufacturing approaches without forcing all submissions into a rigid structure.

4. Digital Transformation Enablement

M4Q(R2) is explicitly designed to support digital submissions with granular, structured, machine-readable data. While it stops short of mandating a specific file standard, it lays essential groundwork for future eCTD 4.0 implementation and AI-powered regulatory analytics.

Implementation Timeline: What to Expect

Current Status (February 2026): M4Q(R2) is at Step 2 of the ICH process, with public consultation that began in May 2025. Comments are due in March 2026.

Expected Steps 3 & 4 Sign-off: June 2027

Implementation: Not expected until 2028, with coordination tied to eCTD 4.0 rollout

Transition Period: The Expert Working Group has recommended adequate transition time post-Step 4 to allow industry and regulators to adapt systems, processes, and vendor tools without disrupting operations.

Preparing for the Transition: Practical Steps

1. Conduct Gap Analysis

Map your current Module 3 content to the new M4Q(R2) structure. Identify which information will migrate to Module 2.3.3 (Core Quality Information) versus 2.3.4 (Development Summary) versus Module 3.2 (Supporting Data).

2. Update SOPs and Templates

Review and revise internal Standard Operating Procedures, submission templates, and authoring guidance to align with M4Q(R2) modular structure and cross-referencing requirements.

3. Enhance QbD Documentation

Strengthen pharmaceutical development documentation to clearly articulate QTPP, critical quality attributes, risk assessments, and control strategy rationale as required in Module 2.3.4.

4. Invest in Digital Infrastructure

Begin transitioning from PDF-based documentation to structured data management systems. Consider knowledge management platforms that support granular data capture, cross-referencing, and automated report generation.

5. Train Teams

Educate regulatory, quality, and CMC teams on M4Q(R2) structure, QbD principles, and the strategic rationale behind the changes. Cross-functional understanding is essential for successful implementation.

6. Monitor Regional Implementation

Track how different ICH regions (FDA, EMA, PMDA, Health Canada, etc.) plan to implement M4Q(R2). Regional timelines may vary, and early adoption options may become available.

Looking Ahead: The Digital Future

M4Q(R2) represents more than a guideline update as it signals the pharmaceutical industry's shift toward data-driven, digital-first regulatory processes. Key trends to watch:

• eCTD 4.0 Development: M4Q(R2) is designed to support future eCTD 4.0 standards, which will likely mandate structured data formats

• AI and Machine Learning: Granular, structured data will enable AI-powered regulatory analytics, automated consistency checks, and predictive review timelines

• Real-World Evidence Integration: Structured quality data frameworks will facilitate integration with real-world manufacturing data and post-market surveillance

• Global Harmonization: M4Q(R2) serves as the central framework for global regulatory quality data, reducing regional fragmentation

Conclusion

M4Q(R2) is a strategic evolution designed to meet the demands of modern pharmaceutical development, advanced therapeutic modalities, and digital transformation. The shift from M4Q(R1) to M4Q(R2) provides:

• Greater clarity and precision in quality module organization
• Enhanced regulatory efficiency through focused Module 2.3
• Flexibility for innovative products and platform technologies
• Foundation for digital-first submissions and lifecycle management
• Integration of quality science principles from ICH Q8-Q14

Organizations that begin preparing now, starting with mapping content, updating processes, investing in digital infrastructure, and training teams, will be well-positioned to adopt M4Q(R2) efficiently when it becomes effective in 2028. This proactive approach ensures submissions are robust, compliant, and aligned with the future of global regulatory science.